Aaron Michels
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 70 | 2026 | 3776 | 7.360 |
Why?
| | Receptors, Antigen, T-Cell | 16 | 2025 | 720 | 3.430 |
Why?
| | Autoantigens | 17 | 2025 | 422 | 3.320 |
Why?
| | Insulin | 30 | 2026 | 2482 | 3.070 |
Why?
| | Islets of Langerhans | 17 | 2025 | 804 | 2.700 |
Why?
| | Autoantibodies | 23 | 2026 | 1470 | 2.610 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 193 | 1.880 |
Why?
| | T-Lymphocytes | 13 | 2025 | 2003 | 1.870 |
Why?
| | Insulin-Secreting Cells | 10 | 2025 | 382 | 1.650 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 257 | 1.630 |
Why?
| | Autoimmunity | 15 | 2025 | 908 | 1.530 |
Why?
| | HLA Antigens | 4 | 2025 | 233 | 1.520 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2025 | 1110 | 1.470 |
Why?
| | Insulin Antibodies | 5 | 2026 | 103 | 1.350 |
Why?
| | Hypoglycemic Agents | 9 | 2020 | 1365 | 1.330 |
Why?
| | Antibodies, Monoclonal | 5 | 2020 | 1448 | 1.240 |
Why?
| | Autoimmune Diseases | 5 | 2019 | 464 | 1.090 |
Why?
| | Peptides | 6 | 2023 | 978 | 1.070 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2018 | 369 | 1.020 |
Why?
| | HLA-DQ Antigens | 7 | 2019 | 178 | 0.990 |
Why?
| | Immunologic Factors | 3 | 2019 | 248 | 0.950 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 228 | 0.910 |
Why?
| | Antigen Presentation | 2 | 2018 | 220 | 0.840 |
Why?
| | Melanoma | 2 | 2022 | 772 | 0.830 |
Why?
| | Protein Precursors | 3 | 2021 | 133 | 0.820 |
Why?
| | B7-H1 Antigen | 3 | 2021 | 221 | 0.760 |
Why?
| | Humans | 81 | 2026 | 141197 | 0.750 |
Why?
| | Models, Immunological | 2 | 2015 | 101 | 0.750 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 97 | 0.750 |
Why?
| | Peptide Fragments | 6 | 2016 | 698 | 0.750 |
Why?
| | Methyldopa | 2 | 2019 | 7 | 0.720 |
Why?
| | Immunotherapy | 7 | 2021 | 641 | 0.720 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2025 | 54 | 0.660 |
Why?
| | HLA-DQ beta-Chains | 1 | 2020 | 62 | 0.650 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.630 |
Why?
| | Disease Susceptibility | 1 | 2021 | 352 | 0.630 |
Why?
| | Health Fairs | 1 | 2019 | 10 | 0.620 |
Why?
| | Interferon-gamma | 2 | 2021 | 792 | 0.620 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2019 | 38 | 0.610 |
Why?
| | Antigens | 4 | 2018 | 362 | 0.600 |
Why?
| | Child | 31 | 2026 | 22310 | 0.570 |
Why?
| | Preventive Medicine | 1 | 2018 | 40 | 0.560 |
Why?
| | Proinsulin | 2 | 2017 | 52 | 0.540 |
Why?
| | Epitopes | 5 | 2025 | 477 | 0.530 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 208 | 0.530 |
Why?
| | Alleles | 5 | 2022 | 891 | 0.530 |
Why?
| | Adolescent | 28 | 2026 | 22007 | 0.510 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.510 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.490 |
Why?
| | Influenza, Human | 1 | 2022 | 626 | 0.490 |
Why?
| | Mice, Inbred NOD | 9 | 2025 | 601 | 0.490 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2363 | 0.480 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 121 | 0.470 |
Why?
| | Major Histocompatibility Complex | 2 | 2013 | 234 | 0.450 |
Why?
| | Graft Rejection | 1 | 2018 | 544 | 0.450 |
Why?
| | Rituximab | 1 | 2016 | 204 | 0.450 |
Why?
| | HLA-D Antigens | 1 | 2014 | 32 | 0.440 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1150 | 0.440 |
Why?
| | Diet Therapy | 1 | 2014 | 37 | 0.430 |
Why?
| | Hypoglycemia | 3 | 2016 | 463 | 0.430 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 914 | 0.430 |
Why?
| | Addison Disease | 1 | 2014 | 42 | 0.420 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 95 | 0.420 |
Why?
| | Biomarkers | 4 | 2025 | 4175 | 0.420 |
Why?
| | Adrenal Glands | 1 | 2014 | 80 | 0.420 |
Why?
| | Young Adult | 19 | 2026 | 13673 | 0.410 |
Why?
| | Antibodies | 1 | 2015 | 409 | 0.410 |
Why?
| | Blood Glucose | 5 | 2026 | 2269 | 0.400 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 101 | 0.400 |
Why?
| | Child, Preschool | 16 | 2026 | 11457 | 0.390 |
Why?
| | Disease Progression | 6 | 2021 | 2793 | 0.380 |
Why?
| | Mass Screening | 3 | 2019 | 1310 | 0.380 |
Why?
| | Male | 37 | 2026 | 69789 | 0.380 |
Why?
| | Female | 40 | 2026 | 75522 | 0.370 |
Why?
| | Prediabetic State | 1 | 2015 | 248 | 0.370 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 78 | 0.340 |
Why?
| | Animals | 23 | 2025 | 37663 | 0.340 |
Why?
| | Glycine | 1 | 2011 | 183 | 0.330 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.330 |
Why?
| | Infant | 10 | 2025 | 9818 | 0.330 |
Why?
| | Struma Ovarii | 1 | 2010 | 7 | 0.330 |
Why?
| | Macromolecular Substances | 1 | 2010 | 226 | 0.320 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 35 | 0.310 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 854 | 0.310 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 335 | 0.300 |
Why?
| | Adult | 29 | 2026 | 39181 | 0.300 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2026 | 852 | 0.290 |
Why?
| | C-Peptide | 5 | 2016 | 167 | 0.290 |
Why?
| | Transcription Factor 7-Like 2 Protein | 2 | 2018 | 26 | 0.280 |
Why?
| | Haplotypes | 3 | 2020 | 496 | 0.280 |
Why?
| | Carbamazepine | 2 | 2019 | 20 | 0.270 |
Why?
| | Inflammation | 2 | 2017 | 2889 | 0.270 |
Why?
| | Glutamate Decarboxylase | 4 | 2017 | 166 | 0.260 |
Why?
| | Pediatrics | 1 | 2015 | 1094 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2020 | 2526 | 0.260 |
Why?
| | Neoplasms | 2 | 2020 | 2741 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2021 | 918 | 0.250 |
Why?
| | Antilymphocyte Serum | 2 | 2016 | 59 | 0.240 |
Why?
| | Middle Aged | 20 | 2022 | 34438 | 0.240 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2016 | 88 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2026 | 855 | 0.230 |
Why?
| | History, 21st Century | 2 | 2018 | 220 | 0.230 |
Why?
| | Mice | 13 | 2025 | 18055 | 0.230 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 697 | 0.220 |
Why?
| | History, 20th Century | 2 | 2018 | 329 | 0.220 |
Why?
| | Endocrinology | 1 | 2025 | 76 | 0.220 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 80 | 0.220 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2024 | 133 | 0.210 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 580 | 0.210 |
Why?
| | Hybridomas | 3 | 2020 | 236 | 0.200 |
Why?
| | Age of Onset | 1 | 2025 | 532 | 0.200 |
Why?
| | Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.200 |
Why?
| | Lipodystrophy | 1 | 2023 | 13 | 0.200 |
Why?
| | Protein Binding | 3 | 2021 | 2239 | 0.200 |
Why?
| | CD3 Complex | 2 | 2020 | 106 | 0.190 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 393 | 0.170 |
Why?
| | Histocompatibility Antigens | 1 | 2021 | 107 | 0.170 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2929 | 0.170 |
Why?
| | Insulin, Regular, Human | 1 | 2020 | 48 | 0.170 |
Why?
| | Rhizotomy | 1 | 2000 | 4 | 0.170 |
Why?
| | Polyethylene Glycols | 2 | 2016 | 638 | 0.170 |
Why?
| | Virus Diseases | 2 | 2015 | 215 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2134 | 0.160 |
Why?
| | Brachial Plexus | 1 | 2000 | 33 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1052 | 0.160 |
Why?
| | Retroviridae | 1 | 2020 | 103 | 0.160 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 209 | 0.160 |
Why?
| | Muscle Spasticity | 1 | 2000 | 61 | 0.160 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 9 | 0.160 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.160 |
Why?
| | Arm | 1 | 2000 | 108 | 0.160 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 60 | 0.160 |
Why?
| | Case-Control Studies | 3 | 2022 | 3588 | 0.160 |
Why?
| | Immunoassay | 1 | 2020 | 113 | 0.150 |
Why?
| | Stem Cells | 2 | 2021 | 602 | 0.150 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 37 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2026 | 11120 | 0.150 |
Why?
| | Genotype | 2 | 2015 | 1859 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 546 | 0.150 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2019 | 174 | 0.150 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 112 | 0.150 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 145 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4073 | 0.140 |
Why?
| | Models, Molecular | 2 | 2015 | 1603 | 0.140 |
Why?
| | Transglutaminases | 2 | 2016 | 156 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 157 | 0.140 |
Why?
| | Community Health Services | 1 | 2019 | 233 | 0.130 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 58 | 0.130 |
Why?
| | Tissue Donors | 2 | 2021 | 405 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 354 | 0.130 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 28 | 0.130 |
Why?
| | Radioimmunoassay | 1 | 2016 | 169 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 653 | 0.130 |
Why?
| | Amino Acid Sequence | 3 | 2017 | 2158 | 0.130 |
Why?
| | Luminescence | 1 | 2016 | 37 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 1000 | 0.120 |
Why?
| | Mutation | 3 | 2015 | 4013 | 0.120 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2181 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 803 | 0.120 |
Why?
| | Luminescent Measurements | 1 | 2016 | 74 | 0.120 |
Why?
| | Dideoxynucleosides | 1 | 2015 | 21 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 75 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2017 | 360 | 0.110 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 159 | 0.110 |
Why?
| | Sensitivity and Specificity | 4 | 2026 | 1973 | 0.110 |
Why?
| | Monocytes | 2 | 2016 | 579 | 0.110 |
Why?
| | Abatacept | 1 | 2014 | 56 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 391 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 41 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 167 | 0.110 |
Why?
| | Early Medical Intervention | 1 | 2014 | 60 | 0.110 |
Why?
| | Multifactorial Inheritance | 1 | 2015 | 178 | 0.110 |
Why?
| | Niacinamide | 1 | 2014 | 82 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 101 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2019 | 858 | 0.100 |
Why?
| | Chromogranin A | 1 | 2013 | 42 | 0.100 |
Why?
| | CD4 Antigens | 1 | 2013 | 141 | 0.100 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 48 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 241 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 310 | 0.100 |
Why?
| | Immunoconjugates | 1 | 2014 | 126 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 104 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 202 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2014 | 151 | 0.100 |
Why?
| | Celiac Disease | 1 | 2016 | 295 | 0.100 |
Why?
| | Colorado | 2 | 2021 | 4610 | 0.100 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 169 | 0.100 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 225 | 0.100 |
Why?
| | Incidence | 1 | 2019 | 2794 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 627 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1074 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2018 | 675 | 0.090 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 188 | 0.090 |
Why?
| | Pancreas, Artificial | 1 | 2013 | 98 | 0.090 |
Why?
| | Aged | 5 | 2021 | 24576 | 0.090 |
Why?
| | Alum Compounds | 1 | 2011 | 27 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 849 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 348 | 0.090 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 98 | 0.080 |
Why?
| | Cytokines | 2 | 2017 | 2098 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2014 | 505 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 579 | 0.080 |
Why?
| | Thyroglobulin | 1 | 2010 | 27 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2011 | 136 | 0.080 |
Why?
| | Whole Body Imaging | 1 | 2010 | 26 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 116 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1498 | 0.080 |
Why?
| | Iodine Radioisotopes | 1 | 2010 | 141 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 97 | 0.080 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 71 | 0.080 |
Why?
| | Self Tolerance | 1 | 2009 | 27 | 0.080 |
Why?
| | Prospective Studies | 4 | 2026 | 7739 | 0.080 |
Why?
| | Organ Specificity | 1 | 2010 | 312 | 0.080 |
Why?
| | Hysterectomy | 1 | 2010 | 138 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2011 | 368 | 0.070 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 29 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 196 | 0.070 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1274 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 453 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 378 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1556 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2599 | 0.060 |
Why?
| | Vaccines | 1 | 2011 | 406 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2017 | 123 | 0.060 |
Why?
| | Area Under Curve | 2 | 2016 | 324 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5887 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 573 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3490 | 0.060 |
Why?
| | Perilipin-1 | 1 | 2023 | 17 | 0.050 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 11 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2022 | 2003 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1828 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 464 | 0.050 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 49 | 0.050 |
Why?
| | Psychology, Child | 1 | 1981 | 39 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1703 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 166 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 128 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 122 | 0.040 |
Why?
| | HLA-B15 Antigen | 1 | 2019 | 12 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 94 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 132 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2020 | 274 | 0.040 |
Why?
| | Hand | 1 | 2000 | 163 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2020 | 184 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2019 | 223 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1197 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2020 | 336 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 338 | 0.040 |
Why?
| | Psychotic Disorders | 1 | 1981 | 178 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2018 | 187 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2023 | 647 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2018 | 86 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 406 | 0.030 |
Why?
| | Gene Editing | 1 | 2018 | 86 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5799 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 494 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 246 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2018 | 188 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 398 | 0.030 |
Why?
| | Receptors, CXCR3 | 1 | 2016 | 12 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 36 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 737 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 77 | 0.030 |
Why?
| | Zinc Transporter 8 | 1 | 2016 | 63 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 499 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 199 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2016 | 109 | 0.030 |
Why?
| | Skin | 1 | 2019 | 765 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 415 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 288 | 0.030 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 53 | 0.030 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.030 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.030 |
Why?
| | Chromatography, Gel | 1 | 2014 | 131 | 0.030 |
Why?
| | Allylamine | 1 | 2013 | 7 | 0.030 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 196 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2772 | 0.030 |
Why?
| | Bromocriptine | 1 | 2013 | 31 | 0.030 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 26 | 0.030 |
Why?
| | Overweight | 1 | 2018 | 587 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2014 | 88 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 358 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4208 | 0.030 |
Why?
| | Risk | 1 | 2016 | 904 | 0.030 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 49 | 0.030 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 48 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1357 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 10438 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 469 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 189 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 434 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1261 | 0.020 |
Why?
| | Thiazolidinediones | 1 | 2013 | 138 | 0.020 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 133 | 0.020 |
Why?
| | Leptin | 1 | 2013 | 242 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2014 | 380 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2013 | 251 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 641 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3348 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2892 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 336 | 0.020 |
Why?
| | Thymus Gland | 1 | 2011 | 319 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1086 | 0.020 |
Why?
| | Metformin | 1 | 2013 | 333 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3166 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4405 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2902 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1491 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2000 | 2797 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5144 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6956 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 3004 | 0.010 |
Why?
| | Registries | 1 | 2013 | 2135 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5636 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2087 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7856 | 0.010 |
Why?
| | Language Development Disorders | 1 | 1981 | 39 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 1981 | 136 | 0.010 |
Why?
| | Child Behavior Disorders | 1 | 1981 | 143 | 0.010 |
Why?
| | Family | 1 | 1981 | 680 | 0.010 |
Why?
| | United States | 1 | 2013 | 15220 | 0.010 |
Why?
| | Communication | 1 | 1981 | 945 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|